메뉴 건너뛰기




Volumn 11, Issue 4, 2012, Pages 250-255

Treatment of chronic HCV genotype 4 infection

Author keywords

HCV4 Pegylated interferon new interferon molecules DAAT; Middle East

Indexed keywords

ALISPORIVIR; ALPHA2A INTERFERON; ASUNAPREVIR; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; MERICITABINE; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; PROTEINASE INHIBITOR; REIFERON RETARD; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VITAMIN D;

EID: 84872271566     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-012-0146-2     Document Type: Article
Times cited : (2)

References (46)
  • 1
    • 30044437827 scopus 로고    scopus 로고
    • American gastroenterological association medical position statement on the management of hepatitis C
    • Dienstag JL, McHutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130:225-30.
    • (2006) Gastroenterology , vol.130 , pp. 225-230
    • Dienstag, J.L.1    McHutchison, J.G.2
  • 2
    • 0036828783 scopus 로고    scopus 로고
    • Course and outcome of hepatitis C
    • Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;5(5 Suppl 1):S21-9.
    • (2002) Hepatology , vol.5 , Issue.5 SUPPL. 1
    • Hoofnagle, J.H.1
  • 3
    • 0028202422 scopus 로고
    • Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey
    • McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884-92.
    • (1994) J Clin Microbiol , vol.32 , pp. 884-892
    • McOmish, F.1    Yap, P.L.2    Dow, B.C.3
  • 5
    • 33947421196 scopus 로고    scopus 로고
    • Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: Comparison of data with that from other Middle Eastern countries
    • Sharara AI, Ramia S, Ramlawi F, et al. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: Comparison of data with that from other Middle Eastern countries. Epidemiol Infect. 2007;135(3):427-32.
    • (2007) Epidemiol Infect , vol.135 , Issue.3 , pp. 427-432
    • Sharara, A.I.1    Ramia, S.2    Ramlawi, F.3
  • 6
    • 33644796135 scopus 로고    scopus 로고
    • Prevalence of viral markers among first-time Arab blood donors in Kuwait
    • Ameen R, Sanad N, Al-Shemmari S, et al. Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion. 2005;45(12):1973-80.
    • (2005) Transfusion , vol.45 , Issue.12 , pp. 1973-1980
    • Ameen, R.1    Sanad, N.2    Al-Shemmari, S.3
  • 7
    • 57649120879 scopus 로고    scopus 로고
    • The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province
    • Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect. 2009;137(1):79-84.
    • (2009) Epidemiol Infect , vol.137 , Issue.1 , pp. 79-84
    • Antaki, N.1    Haddad, M.2    Kebbewar, K.3
  • 8
    • 0031670838 scopus 로고    scopus 로고
    • Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip
    • Shemer-Avni Y, El Astal Z, Kemper O, et al. Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. J Med Virol. 1998;56(3):230-3.
    • (1998) J Med Virol , vol.56 , Issue.3 , pp. 230-233
    • Shemer-Avni, Y.1    El Astal, Z.2    Kemper, O.3
  • 9
    • 0028132879 scopus 로고
    • Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon)
    • Xu L-Z, Larzul D, Delaporte E, et al. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol. 1994;75:2393-8.
    • (1994) J Gen Virol , vol.75 , pp. 2393-2398
    • Xu, L.-Z.1    Larzul, D.2    Delaporte, E.3
  • 10
    • 0041852686 scopus 로고    scopus 로고
    • Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon
    • Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol. 2003;84:2333-41.
    • (2003) J Gen Virol , vol.84 , pp. 2333-2341
    • Ndjomou, J.1    Pybus, O.G.2    Matz, B.3
  • 11
    • 0031765060 scopus 로고    scopus 로고
    • Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana
    • Wansbrough-Jones MH, Frimpong E, Cant B, et al. Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Trans R Soc Tropical Med Hyg. 1998;92:496-9.
    • (1998) Trans R Soc Tropical Med Hyg , vol.92 , pp. 496-499
    • Wansbrough-Jones, M.H.1    Frimpong, E.2    Cant, B.3
  • 12
    • 80455148814 scopus 로고    scopus 로고
    • (DHS-) This survey is considered the first epidemiological geographical-based survey done in Egypt for many health problems like HCV, nutrition, maternal health care, etc
    • Egypt Demographic and Health Survey (DHS-2008): http://www.measuredhs. com/pubs. This survey is considered the first epidemiological geographical-based survey done in Egypt for many health problems like HCV, nutrition, maternal health care, etc.
    • (2008) Egypt Demographic and Health Survey
  • 13
    • 0033831605 scopus 로고    scopus 로고
    • Genetic epidemiology of hepatitis C virus throughout Egypt
    • Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182:698-707.
    • (2000) J Infect Dis , vol.182 , pp. 698-707
    • Ray, S.C.1    Arthur, R.R.2    Carella, A.3
  • 14
    • 0343376130 scopus 로고    scopus 로고
    • Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain
    • Sanchez Quijano A, Abad MA, Torronteras R, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol. 1997;27:25-9.
    • (1997) J Hepatol , vol.27 , pp. 25-29
    • Sanchez Quijano, A.1    Abad, M.A.2    Torronteras, R.3
  • 15
    • 0036197285 scopus 로고    scopus 로고
    • Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy
    • Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis. 2002;42:169-73.
    • (2002) Diagn Microbiol Infect Dis , vol.42 , pp. 169-173
    • Matera, G.1    Lamberti, A.2    Quirino, A.3
  • 16
    • 17644444758 scopus 로고    scopus 로고
    • Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country
    • Remy AJ, Verdier E, Perney P, et al. Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country. J Hepatol. 1998;29:169.
    • (1998) J Hepatol , vol.29 , pp. 169
    • Remy, A.J.1    Verdier, E.2    Perney, P.3
  • 17
    • 79956074037 scopus 로고    scopus 로고
    • Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel
    • Khattab MA, Ferenci P, Stephanos J, et al. Management of hepatitis C virus genotype 4: recommendations of An International Expert Panel. J Hepatol. 2011;54(6):1250-62.
    • (2011) J Hepatol , vol.54 , Issue.6 , pp. 1250-1262
    • Khattab, M.A.1    Ferenci, P.2    Stephanos, J.3
  • 18
    • 33747797031 scopus 로고    scopus 로고
    • Treating viral hepatitis side effects, and complications
    • Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis side effects, and complications. Gut. 2006;55:1350-9.
    • (2006) Gut , vol.55 , pp. 1350-1359
    • Manns, M.P.1    Wedemeyer, H.2    Cornberg, M.3
  • 19
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 20
    • 84872261741 scopus 로고    scopus 로고
    • Accepted poster (AASLD). The study showed a similar efficacy for both once weekly Yshaped interferon regimen VS once/2 weeks, this leads to minimizing the side effects and lowering the treatment costs especially in developing countries
    • Ashour MK, Elraziky M, El Akel W, et al. Safety, Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster (AASLD 2011). The study showed a similar efficacy for both once weekly Yshaped interferon regimen VS once/2 weeks, this leads to minimizing the side effects and lowering the treatment costs especially in developing countries.
    • (2011) Safety, Dosage and Efficacy of A Novel y Shaped Molecule of Pegylated Interferon Alpha 2a for Treatment of Chronic HCV
    • Ashour, M.K.1    Elraziky, M.2    El Akel, W.3
  • 21
    • 66649111875 scopus 로고    scopus 로고
    • Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis Cgenotype 4
    • This novel cheap molecule of pegylated Interferon showed comparable results to the ordinary known forms of pegylated Interferon in early fibrosis stages (F1, F2)
    • Esmat G, Abdel Fattah S. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis Cgenotype 4. Digestive and Liver Disease Supplement. 2009;3(1):17-19. This novel cheap molecule of pegylated Interferon showed comparable results to the ordinary known forms of pegylated Interferon in early fibrosis stages (F1, F2).
    • (2009) Digestive and Liver Disease Supplement , vol.3 , Issue.1 , pp. 17-19
    • Esmat, G.1    Abdel Fattah, S.2
  • 22
    • 77958470624 scopus 로고    scopus 로고
    • Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C
    • Taha AA, El-Ray A, El-Ghannam M, et al. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol. 2010;24 (10):597-602.
    • (2010) Can J Gastroenterol , vol.24 , Issue.10 , pp. 597-602
    • Taha, A.A.1    El-Ray, A.2    El-Ghannam, M.3
  • 23
    • 78650928878 scopus 로고    scopus 로고
    • New direct-acting antivirals' combination for the treatment of chronic hepatitis C
    • Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011;31 Suppl 1:68-77.
    • (2011) Liver Int , vol.31 , Issue.SUPPL. 1 , pp. 68-77
    • Asselah, T.1    Marcellin, P.2
  • 24
    • 36749001029 scopus 로고    scopus 로고
    • The way forward in HCV treatmentfinding the right path
    • Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatmentfinding the right path. Nat Rev Drug Discov. 2007;6:991-1000.
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 991-1000
    • Manns, M.P.1    Foster, G.R.2    Rockstroh, J.K.3
  • 25
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-38.
    • (2009) N Engl J Med , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1    Everson, G.T.2    Gordon, S.C.3
  • 26
    • 77950817619 scopus 로고    scopus 로고
    • Telaprevir for previously treated chronic HCV infection
    • McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-303.
    • (2010) N Engl J Med , vol.362 , pp. 1292-1303
    • McHutchison, J.G.1    Manns, M.P.2    Muir, A.J.3
  • 27
    • 67650694266 scopus 로고    scopus 로고
    • Results of a proof of concept study (C210) of Telaprevir Monotherapy and in combination with peginterferon alfa-2a and Ribavirin in treatment-naive genotype 4 HCV patients
    • Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of Telaprevir Monotherapy and in combination with peginterferon alfa-2a and Ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol. 2009;50:S6.
    • (2009) J Hepatol , vol.50
    • Benhamou, Y.1    Moussalli, J.2    Ratziu, V.3
  • 28
    • 57049176125 scopus 로고    scopus 로고
    • Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)
    • Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52:4432-41.
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 4432-4441
    • Seiwert, S.D.1    Andrews, S.W.2    Jiang, Y.3
  • 29
    • 84861188748 scopus 로고    scopus 로고
    • Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
    • Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56(6):1247-53.
    • (2012) J Hepatol , vol.56 , Issue.6 , pp. 1247-1253
    • Moreno, C.1    Berg, T.2    Tanwandee, T.3
  • 30
    • 78751634051 scopus 로고    scopus 로고
    • High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40 KD)/RBV: Planned Week 12interim analysis from the PROPEL study
    • abstract 81
    • Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40 KD)/RBV: Planned Week 12interim analysis from the PROPEL study. Hepatology 2010;52:(abstract 81).
    • (2010) Hepatology , vol.52
    • Jensen, D.M.1    Wedemeyer, H.2    Herring, R.W.3
  • 31
    • 66149129922 scopus 로고    scopus 로고
    • The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients
    • Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology. 2009;49:1460-8.
    • (2009) Hepatology , vol.49 , pp. 1460-1468
    • Flisiak, R.1    Feinman, S.V.2    Jablkowski, M.3
  • 32
    • 80053951840 scopus 로고    scopus 로고
    • HCV NS5A inhibitors modulate multiple aspects of NS5A expression
    • Qiu D, Lemm JA, O'Boyle 2nd DR, et al. HCV NS5A Inhibitors Modulate Multiple Aspects of NS5A Expression. J Gen Virol. 2011;92:2502-11.
    • (2011) J Gen Virol , vol.92 , pp. 2502-2511
    • Qiu, D.1    Lemm, J.A.2    O'Boyle, I.I.D.R.3
  • 34
    • 70350125916 scopus 로고    scopus 로고
    • The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation
    • Elazar M, Liu M, McKenna SA, et al. The antihepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009;137:1827-35.
    • (2009) Gastroenterology , vol.137 , pp. 1827-1835
    • Elazar, M.1    Liu, M.2    McKenna, S.A.3
  • 35
    • 48449084880 scopus 로고    scopus 로고
    • Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
    • Rossignol JF, Kabil SM, El Gohary Y. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-80.
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 574-580
    • Rossignol, J.F.1    Kabil, S.M.2    El Gohary, Y.3
  • 36
    • 67650558979 scopus 로고    scopus 로고
    • Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges?
    • Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Ann Hepatol. 2009;8:166-8.
    • (2009) Ann Hepatol , vol.8 , pp. 166-168
    • Mederacke, I.1    Wedemeyer, H.2
  • 37
    • 84872268551 scopus 로고    scopus 로고
    • Potent Viral Suppression with All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-Ribavirin
    • in Treatment-Naive Patients with Chronic HCV GT1, 2, or 3. (EASL). Barcelona, April 18-22, 2012. Abstract 1422
    • Sulkowski M, Gardiner D, Lawitz E, et al. Potent Viral Suppression with All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor), +/-Ribavirin, in Treatment-Naive Patients with Chronic HCV GT1, 2, or 3. 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). Barcelona, April 18-22, 2012. Abstract 1422.
    • (2012) 47th Annual Meeting of the European Association for the Study of the Liver
    • Sulkowski, M.1    Gardiner, D.2    Lawitz, E.3
  • 38
    • 84867402086 scopus 로고    scopus 로고
    • Dual Oral Therapy with the NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1binfected Null Responders or Ineligible/Intolerant to Peginterferon
    • (EASL) Barcelona, April 18-22, 2012. Abstract 14
    • Suzuki F, Ikeda K, Toyota J, et al. Dual Oral Therapy with the NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1binfected Null Responders or Ineligible/Intolerant to Peginterferon. 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). Barcelona, April 18-22, 2012. Abstract 14.
    • (2012) 47th Annual Meeting of the European Association for the Study of the Liver
    • Suzuki, F.1    Ikeda, K.2    Toyota, J.3
  • 39
    • 21144449073 scopus 로고    scopus 로고
    • Peginterferon a-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response
    • Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon a-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54:858-66.
    • (2005) Gut , vol.54 , pp. 858-866
    • Kamal, S.M.1    El Tawil, A.A.2    Nakano, T.3
  • 40
    • 67650132966 scopus 로고    scopus 로고
    • Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin
    • Elefsiniotis IS, Vezali E, Mihas C, et al. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology. 2009;52:247-51.
    • (2009) Intervirology , vol.52 , pp. 247-251
    • Elefsiniotis, I.S.1    Vezali, E.2    Mihas, C.3
  • 41
    • 84856849283 scopus 로고    scopus 로고
    • Pegylated interferonalpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT
    • Al-Ali J, Siddique I, Varghese R, et al. Pegylated interferonalpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Ann Hepatol. 2012;11(2):186-93.
    • (2012) Ann Hepatol , vol.11 , Issue.2 , pp. 186-193
    • Al-Ali, J.1    Siddique, I.2    Varghese, R.3
  • 42
    • 34250625319 scopus 로고    scopus 로고
    • Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection
    • Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis. 2007;14:460-7.
    • (2007) Journal of Viral Hepatitis , vol.14 , pp. 460-467
    • Roulot, D.1    Bourcier, V.2    Grando, V.3
  • 43
    • 68949098506 scopus 로고    scopus 로고
    • Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4
    • El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009;81(9):1576-83.
    • (2009) J Med Virol , vol.81 , Issue.9 , pp. 1576-1583
    • El Makhzangy, H.1    Esmat, G.2    Said, M.3
  • 44
    • 79959618797 scopus 로고    scopus 로고
    • Hepatitis C virus genotype 4 with normal transaminases: Histological changes, schistosomiasis and response to treatment
    • Derbala MF, Amer AM, Almohanadi M, et al. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. J Viral Hepat. 2011;18 (7):e258-62.
    • (2011) J Viral Hepat , vol.18 , Issue.7
    • Derbala, M.F.1    Amer, A.M.2    Almohanadi, M.3
  • 45
    • 64949119373 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin
    • Varghese R, Al-Khaldi J, Asker H, et al. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology. 2009;56(89):218-22.
    • (2009) Hepatogastroenterology , vol.56 , Issue.89 , pp. 218-222
    • Varghese, R.1    Al-Khaldi, J.2    Asker, H.3
  • 46
    • 37749046123 scopus 로고    scopus 로고
    • Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
    • Kamal SM, Elkamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology. 2007;46:1732-40.
    • (2007) Hepatology , vol.46 , pp. 1732-1740
    • Kamal, S.M.1    Elkamary, S.S.2    Shardell, M.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.